Rheumatoid Arthritis: Symptoms, Diagnosis and Treatment

Morning stiffness that takes more than an hour to ease. Swollen, tender knuckles — symmetrically, both hands. This is not "just tiredness" or wear-and-tear arthritis: this picture is the classic onset of rheumatoid arthritis. The disease affects roughly 1% of the world's population and is three times more common in women than men. The earlier the diagnosis, the greater the chance of preserving joint function for decades to come. This article covers everything essential: symptoms, diagnostic tests, and treatment.

What Is Rheumatoid Arthritis and How It Develops

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks the synovial lining of joints. The synovium — a thin membrane that produces lubricating fluid — becomes inflamed, thickens, and begins to proliferate. The result is a structure called pannus: aggressive inflammatory tissue that literally erodes cartilage and the underlying bone. Without treatment, RA leads to irreversible joint destruction within a few years.

The key mechanism: citrullination of synovial proteins triggers an autoimmune response — the immune system begins producing antibodies against its own tissues. This process can start years before the first symptoms appear: anti-CCP antibodies and rheumatoid factor may already be positive in the blood while the joints still look and feel normal.

The precise cause of RA is unknown. Identified risk factors include female sex (oestrogens modulate immune regulation), genetic susceptibility (HLA-DRB1 variants), smoking (the strongest modifiable risk factor — it doubles or triples RA risk), and chronic periodontal disease. The "silent" phase — from antibody appearance to first symptoms — can span 5–10 years.

RA is not confined to joints. In systemic disease, the lungs (interstitial pneumonitis), blood vessels (rheumatoid vasculitis), pericardium, eyes (episcleritis), and peripheral nerves are all potential targets. Systemic manifestations correlate with high antibody titres and aggressive disease course.

Early Symptoms of Rheumatoid Arthritis

Recognising RA early is challenging: the disease disguises itself well. Between first symptoms and diagnosis, an average of 6–12 months passes — and this time is not harmless. Early bone erosions begin forming within the first months of active synovitis.

Morning stiffness is the most characteristic early sign. Joints need at least 30–60 minutes — often longer than an hour — to loosen up. This duration distinguishes inflammatory arthritis from mechanical osteoarthritis, where stiffness resolves within a few minutes.

Symmetrical involvement of small joints is the second hallmark. The classic pattern: the metacarpophalangeal and proximal interphalangeal joints of the hands, and the metatarsophalangeal joints of the feet. Distal interphalangeal joints (closest to the fingertips) are typically spared in RA — a clinically useful distinguishing feature.

Swelling and tenderness on palpation — joints are visibly puffy, warm to touch, and painful when pressed. Unlike gout, the pain in RA is constant rather than arriving in acute attacks.

Systemic symptoms — fatigue, low-grade fever (37.0–37.5°C), weight loss, reduced appetite — frequently precede joint involvement by weeks. This is systemic inflammation, not simply "joint pain."

Symptoms requiring prompt attention. Progressive symptoms for more than six weeks without obvious trauma, viral illness, or another identifiable cause; firm subcutaneous nodules over the elbows, occiput, or sacrum; persistent joint swelling unresponsive to standard pain relief.

Diagnosis of Rheumatoid Arthritis: Which Tests Are Needed

The diagnosis of RA is established against a composite of clinical, laboratory, and imaging findings under the ACR/EULAR 2010 classification criteria. No single test is sufficient.

A complete blood count is the first step. In active RA: normochromic or mildly hypochromic anaemia (anaemia of chronic disease), thrombocytosis, mild or normal leucocytosis, and elevated ESR (above 40–50 mm/h in high disease activity) are the expected pattern.

Serological markers are the backbone of laboratory diagnosis. Anti-CCP antibodies have a specificity above 95% for RA and may appear years before clinical manifestations. Rheumatoid factor is less specific but, when combined with positive anti-CCP, the probability of RA exceeds 95%.

Inflammatory markers. C-reactive protein and ESR reflect current inflammatory activity and are used to assess treatment response and monitor remission. Normalisation of CRP and ESR on therapy is a reliable indicator of remission.

Imaging. Plain radiographs of the hands and feet are the standard for initial diagnosis and monitoring of structural damage. However, early erosions are not visible on X-ray: MRI and joint ultrasound detect synovitis and erosions 2–3 years before radiographic changes appear. In early arthritis (under six months), MRI is the preferred imaging modality.

Reference Values and Interpretation of RA Blood Tests

Serological results are always interpreted alongside the clinical picture — isolated elevated markers without symptoms are not sufficient for diagnosis.

Marker	Normal	Significance in RA
Anti-CCP	< 17 U/mL	> 17 positive; > 200 U/mL strongly positive
Rheumatoid factor	< 14 IU/mL	> 14 positive; > 100 IU/mL high titre
CRP	< 5 mg/L	In active RA: 20–100 mg/L or higher
ESR	< 20 mm/h women, < 15 mm/h men	In active RA: 40–80 mm/h

Disease activity is quantified using the DAS28 (Disease Activity Score in 28 joints) and SDAI indices, which aggregate tender and swollen joint counts, ESR or CRP, and the patient's global assessment. These are the rheumatologist's standard working tools: remission, low, moderate, or high activity — each category has specific numerical thresholds.

Seronegative RA — approximately 20–30% of patients have negative anti-CCP and RF despite a clinically convincing picture. In these cases diagnosis rests on clinical criteria, imaging findings, and exclusion of other arthropathies. Seronegative disease is not necessarily milder: a subset of these patients experiences significant joint destruction.

Treatment of Rheumatoid Arthritis: Modern Approaches

The goal of RA treatment is remission or low disease activity. This is not aspirational: with timely therapy, remission is achieved in 40–60% of patients.

Treat-to-target strategy — the current standard of care. Disease activity is assessed every 1–3 months; if the target is not met within 3–6 months, the treatment regimen is changed. Delaying therapy escalation is the single most common reason for progressive joint destruction.

Conventional synthetic DMARDs (csDMARDs) — the foundation of treatment. Methotrexate is the "gold standard" first-line agent: it reduces disease activity, slows joint destruction, and is well tolerated at appropriate doses. Mandatory co-prescription of folic acid reduces the incidence of side effects. In cases of contraindication or intolerance: leflunomide or sulfasalazine.

Biological DMARDs are added when response to csDMARDs is insufficient. TNF-α inhibitors (adalimumab, etanercept, infliximab), IL-6 inhibitors (tocilizumab), B-cell depleting agents (rituximab). They reduce disease activity in most patients refractory to conventional therapy.

JAK inhibitors (tofacitinib, baricitinib, upadacitinib) — oral targeted synthetic DMARDs. Comparable in efficacy to biologics, convenient to administer.

NSAIDs (ibuprofen, naproxen, diclofenac) — symptomatic relief of pain and stiffness. They do not modify disease progression and are not disease-modifying agents. Long-term use requires gastric protection with a proton pump inhibitor.

Glucocorticoids (prednisolone) — used in low doses as a bridge while awaiting DMARD effect and during flares. Prolonged high-dose use is avoided due to cumulative side effects.

Complications and Comorbidities

RA is a systemic disease with a broad spectrum of extra-articular manifestations and comorbid conditions.

Osteoporosis is one of the most common complications. Chronic inflammation, reduced mobility, and glucocorticoid use together deplete bone mineral density. Patients with RA receiving glucocorticoids should have baseline densitometry and receive prophylactic calcium and vitamin D.

Cardiovascular disease. Chronic systemic inflammation in RA accelerates atherogenesis — the risk of myocardial infarction and stroke is roughly twice that of the general population. This is comparable to the cardiovascular risk conferred by metabolic syndrome, which is why cardiovascular risk reduction (blood pressure, lipids, smoking cessation) is formally part of RA management.

Differential diagnosis of RA includes several conditions with overlapping presentations. Systemic lupus erythematosus (SLE) — an autoimmune disease with joint involvement, the characteristic facial butterfly rash, and specific antibodies (anti-dsDNA). Psoriatic arthritis — joint inflammation in psoriasis, often affecting distal joints and nails. Gout — crystal arthritis caused by urate deposition, presenting with acute attacks predominantly affecting the first metatarsophalangeal joint.

Interstitial lung disease develops in 10–20% of patients with long-standing RA and high antibody titres. Exertional breathlessness and dry cough in a patient with RA are a reason for immediate pulmonary investigation.

When to See a Doctor Urgently

In established or suspected RA, seek emergency care or call emergency services immediately if:

• Sudden severe swelling, redness, and intense pain in a single large joint (knee, elbow, ankle) — possible septic arthritis or crystal arthropathy, requiring urgent aspiration and treatment.
• Progressive breathlessness and cough in a patient with RA taking methotrexate — methotrexate-induced pneumonitis must be excluded promptly.
• High fever (above 38.5°C) on biologic therapy — risk of severe infection; immunosuppression masks classical infective signs.
• First-ever morning stiffness lasting more than 30 minutes with symmetrical small-joint involvement persisting for more than six weeks — the "window of opportunity" for early therapy is open; delay in rheumatology referral directly affects long-term prognosis.
• Marked increase in pain and structural progression on current therapy — indication for treatment escalation or regimen change.

This article is for informational purposes only and does not replace medical consultation. Result interpretation and diagnosis are made by a qualified physician.